NCT06661720
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06661720
Title Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer (STRIKE)
Acronym STRIKE
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Alliance for Clinical Trials in Oncology
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.